PL3423087T3 - Skojarzona terapia przeciwnowotworowa - Google Patents

Skojarzona terapia przeciwnowotworowa

Info

Publication number
PL3423087T3
PL3423087T3 PL17709038.8T PL17709038T PL3423087T3 PL 3423087 T3 PL3423087 T3 PL 3423087T3 PL 17709038 T PL17709038 T PL 17709038T PL 3423087 T3 PL3423087 T3 PL 3423087T3
Authority
PL
Poland
Prior art keywords
cancer therapy
combination anti
combination
cancer
therapy
Prior art date
Application number
PL17709038.8T
Other languages
English (en)
Inventor
Mads Hald Andersen
Original Assignee
Io Biotech Aps
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1603805.1A external-priority patent/GB201603805D0/en
Priority claimed from GBGB1610018.2A external-priority patent/GB201610018D0/en
Application filed by Io Biotech Aps filed Critical Io Biotech Aps
Publication of PL3423087T3 publication Critical patent/PL3423087T3/pl

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001102—Receptors, cell surface antigens or cell surface determinants
    • A61K39/001111—Immunoglobulin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A61K39/0011—Cancer antigens
    • A61K39/001154—Enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55511—Organic adjuvants
    • A61K2039/55566—Emulsions, e.g. Freund's adjuvant, MF59
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
    • A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Microbiology (AREA)
  • Epidemiology (AREA)
  • Mycology (AREA)
  • Immunology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cell Biology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
PL17709038.8T 2016-03-04 2017-03-03 Skojarzona terapia przeciwnowotworowa PL3423087T3 (pl)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1603805.1A GB201603805D0 (en) 2016-03-04 2016-03-04 Combination
GBGB1610018.2A GB201610018D0 (en) 2016-06-08 2016-06-08 Combination
PCT/EP2017/055093 WO2017149150A1 (en) 2016-03-04 2017-03-03 Combination therapy against cancer

Publications (1)

Publication Number Publication Date
PL3423087T3 true PL3423087T3 (pl) 2024-05-20

Family

ID=58231605

Family Applications (1)

Application Number Title Priority Date Filing Date
PL17709038.8T PL3423087T3 (pl) 2016-03-04 2017-03-03 Skojarzona terapia przeciwnowotworowa

Country Status (13)

Country Link
US (2) US20190343940A1 (pl)
EP (2) EP4316517A3 (pl)
JP (3) JP2019507180A (pl)
DK (1) DK3423087T3 (pl)
ES (1) ES2965009T3 (pl)
FI (1) FI3423087T3 (pl)
HR (1) HRP20240052T1 (pl)
HU (1) HUE064857T2 (pl)
LT (1) LT3423087T (pl)
PL (1) PL3423087T3 (pl)
PT (1) PT3423087T (pl)
SI (1) SI3423087T1 (pl)
WO (1) WO2017149150A1 (pl)

Families Citing this family (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2986765A1 (en) 2015-05-29 2016-12-08 Agenus Inc. Anti-ctla-4 antibodies and methods of use thereof
JP6936221B2 (ja) 2015-11-02 2021-09-15 ファイブ プライム セラピューティクス， インコーポレイテッド Ｃｄ８０細胞外ドメインポリペプチドと、がん治療でのそれらの使用
EP4316517A3 (en) * 2016-03-04 2024-05-29 IO Biotech ApS Combination therapy against cancer
KR102576042B1 (ko) 2016-10-11 2023-09-07 아게누스 인코포레이티드 항-lag-3 항체 및 이의 사용 방법
FI3551660T3 (fi) 2016-12-07 2023-12-11 Agenus Inc Anti-ctla-4-vasta-aineita ja niiden käyttömenetelmiä
AU2018258661A1 (en) 2017-04-28 2019-10-17 Five Prime Therapeutics, Inc. Methods of treatment with CD80 extracellular domain polypeptides
TWI817952B (zh) 2017-08-25 2023-10-11 美商戊瑞治療有限公司 Ｂ７－ｈ４抗體及其使用方法
WO2019102265A1 (en) 2017-11-23 2019-05-31 Theraphage Inc. Peptide displaying bacteriophage nanoparticles and related compositions and methods
CN111372656A (zh) * 2017-11-24 2020-07-03 Io生物技术公司 抗体依赖性细胞介导的细胞毒性(adcc)的增强
BR112020016986A2 (pt) 2018-02-21 2021-03-02 Five Prime Therapeutics, Inc. formulações de anticorpo contra b7-h4
CA3091801A1 (en) 2018-03-02 2019-09-06 Five Prime Therapeutics, Inc. B7-h4 antibodies and methods of use thereof
GB201818576D0 (en) * 2018-11-14 2018-12-26 Io Biotech Aps Arginase 2 polypeptides
TW202045544A (zh) 2019-02-22 2020-12-16 美商戊瑞治療有限公司 用於治療ＰＤ－Ｌ１陰性腫瘤之ＣＤ８０胞外結構域Ｆｃ融合蛋白
KR102653960B1 (ko) * 2020-07-23 2024-04-03 의료법인 성광의료재단 암 치료를 위한 면역체크포인트 억제제의 병용 요법
AU2022228701A1 (en) 2021-03-05 2023-09-14 Universität Basel Compositions for the treatment of ebv associated diseases or conditions
EP4052705A1 (en) 2021-03-05 2022-09-07 Universität Basel Vizerektorat Forschung Compositions for the treatment of ebv associated diseases or conditions
GB202103673D0 (en) * 2021-03-17 2021-04-28 Io Biotech Aps Combination therapy for cancer
WO2022245841A1 (en) * 2021-05-17 2022-11-24 Wisconsin Alumni Research Foundation Synthetic protein for inducing immune tolerance
US20250213664A1 (en) * 2022-02-18 2025-07-03 Modernatx, Inc. Mrnas encoding checkpoint cancer vaccines and uses thereof
WO2023161350A1 (en) 2022-02-24 2023-08-31 Io Biotech Aps Nucleotide delivery of cancer therapy
WO2026008017A1 (en) * 2024-07-03 2026-01-08 Everest Medicines (China) Co., Ltd. Cancer vaccines and uses thereof

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US58767A (en) 1866-10-16 John brougjbton
US5554372A (en) 1986-09-22 1996-09-10 Emory University Methods and vaccines comprising surface-active copolymers
US20100055111A1 (en) * 2007-02-14 2010-03-04 Med. College Of Georgia Research Institute, Inc. Indoleamine 2,3-dioxygenase, pd-1/pd-l pathways, and ctla4 pathways in the activation of regulatory t cells
NO2280721T3 (pl) * 2008-04-17 2018-04-14
CA2850245C (en) * 2011-10-17 2020-04-28 Herlev Hospital Pd-l1 based immunotherapy
GB201311475D0 (en) 2013-06-27 2013-08-14 Alligator Bioscience Ab Polypeptides
SG10201806297VA (en) * 2014-02-04 2018-08-30 Incyte Corp Combination of a pd-1 antagonist and an ido1 inhibitor for treating cancer
CA2947687C (en) * 2014-05-30 2021-07-06 Ventana Medical Systems, Inc. Multiplex assay for improved scoring of tumor tissues stained for pd-l1
EP4316517A3 (en) * 2016-03-04 2024-05-29 IO Biotech ApS Combination therapy against cancer

Also Published As

Publication number Publication date
EP4316517A2 (en) 2024-02-07
ES2965009T3 (es) 2024-04-10
JP7417645B2 (ja) 2024-01-18
EP4316517A3 (en) 2024-05-29
FI3423087T3 (fi) 2023-12-15
EP3423087B1 (en) 2023-11-15
DK3423087T3 (da) 2023-12-18
JP2024045180A (ja) 2024-04-02
JP2022068348A (ja) 2022-05-09
HRP20240052T1 (hr) 2024-03-29
JP7785817B2 (ja) 2025-12-15
EP3423087A1 (en) 2019-01-09
PT3423087T (pt) 2023-12-28
WO2017149150A1 (en) 2017-09-08
JP2019507180A (ja) 2019-03-14
SI3423087T1 (sl) 2024-03-29
US20220257741A1 (en) 2022-08-18
HUE064857T2 (hu) 2024-04-28
US20190343940A1 (en) 2019-11-14
LT3423087T (lt) 2024-01-25

Similar Documents

Publication Publication Date Title
EP3463464A4 (en) ASSOCIATION TREATMENT
EP3368656A4 (en) TARGETED CANCER THERAPY
EP3563835A4 (en) NEW EXOSOME-BASED ANTI-CANCER AGENT
DK3328880T3 (da) Terapeutiske midler
EP3291824A4 (en) ANTIMICROBIAL THERAPY
DK3240801T3 (da) Kombinationstumorimmunterapi
EP3499651A4 (en) Connector
EP3445380C0 (en) BACTERIOTHERAPY
PL3622953T3 (pl) Leczenie skojarzone nowotworu
EP3424940A4 (en) Radiolabeled drug
EP3297102A4 (en) Connector
EP3345041C0 (en) BIDIRECTIONAL COLLIMATOR
EP3413927A4 (en) CANCER THERAPY
IL260347A (en) Therapeutic anti-cd9 antibody
DK3408265T3 (da) Terapeutiske forbindelser
IL262851A (en) Combination prime: boost therapy
DK3393478T3 (da) Kombinationsterapi
EP3362091A4 (en) COMBINATION THERAPY
EP3246047C0 (en) COMBINATION MEDICATION
EP3437644A4 (en) MEDICINE
EP3541931A4 (en) COMBINED FRACTAL TREATMENT
EP3256115A4 (en) COMBINATION CANCER THERAPY
EP3527216A4 (en) MEDICINE
DK3432901T3 (da) Sekventiel antikræftbehandling
EP3334447A4 (en) CCK2R-drug conjugates